Johns Hopkins ABX Guide
Pyrazinamide
INDICATIONS
FDA
FDA
- TB (active treatment in combination with other antituberculous drugs)
- Treatment of active tuberculosis (in combination with other antituberculous drugs); no longer recommended for treatment of latent tuberculosis infection because of hepatotoxicity.
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: July 3, 2026
Citation
Avdic, Edina, and Paul A Pham. "Pyrazinamide." Johns Hopkins ABX Guide, The Johns Hopkins University, 2026. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540461/all/Pyrazinamide.
Avdic E, Pham PA. Pyrazinamide. Johns Hopkins ABX Guide. The Johns Hopkins University; 2026. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540461/all/Pyrazinamide. Accessed July 9, 2026.
Avdic, E., & Pham, P. A. (2026). Pyrazinamide. In Johns Hopkins ABX Guide. The Johns Hopkins University. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540461/all/Pyrazinamide
Avdic E, Pham PA. Pyrazinamide [Internet]. In: Johns Hopkins ABX Guide. The Johns Hopkins University; 2026. [cited 2026 July 09]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540461/all/Pyrazinamide.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Pyrazinamide
ID - 540461
A1 - Avdic,Edina,Pharm.D.
AU - Pham,Paul,Pharm.D.
Y1 - 2026/07/03/
BT - Johns Hopkins ABX Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540461/all/Pyrazinamide
PB - The Johns Hopkins University
DB - Pediatrics Central
DP - Unbound Medicine
ER -
